

# Current Pattern of Antibiotic Resistance in Clinical Isolates of *Acinetobacter Baumannii* from Intensive Care Units of Tertiary Care Hospital

Ishrat Irfan Ali,<sup>1</sup> Irfan Ali Khan,<sup>2</sup> Muhammad Kashif Munir,<sup>3</sup> Sheikh Ajaz Rasool<sup>4</sup>

## Abstract

**Purpose:** To determine the pattern of antibiotic resistance in clinical isolates of *Acinetobacter baumannii* from ICU's of tertiary care hospital in Karachi.

**Study Design:** A case control study.

**Methods:** Three hundred and fifteen clinical isolates of *Acinetobacter baumannii* collected from different ICUs were evaluated during 1 year period. The isolates were identified by morphology, growth and biochemical characteristics, susceptibility to a panel of antimicrobial agents in disc diffusion assay and molecular characterization by PCR using *glt A* and *gyr B* genes.

**Results:** 94% of *Acinetobacter* spp were detected as

multi drug resistant (MDR) and sensitive to Polymixin B only. About 6% *Acinetobacter* spp were also MDR but sensitive to Polymixin B, Meropenem and Salbactam + Cefoperazone. All tested isolates exhibited differing resistance representation, as establish by medium incorporation – replica method, against different tested antibiotics, as follows: Amoxicillin – Clavulanic acid, Tazobactam, Ceftriaxone, Ceftazidime, Meropenem, Imipenem, Gentamicin, Amikacin, Chloramphenicol, Co-trimoxazole, Tobramycin, Salbactam, Cefoperazone, Gentamicin and Amikacin. All the isolates of *Acinetobacter baumannii* were PCR positive for *glt A* and *gyr B*.

**Conclusions:** *Acinetobacter baumannii* is the most frequently isolated and alarming pathogen in the health care system specifically for the patients in intensive care units (ICUs). Its survival in hospital environment is because of tolerance the antibiotics and antiseptic pressures. Multi drug resistance made this pathogen the lethal pathogen of this century to infect debilitated patients. There is a strict need to monitor the surveillance of global clones at institutional and or intra-institutional level for accurate treatment, precise prevention and better control.

**Key Words:** Multidrug resistance (MDR), house-keeping genes.

Conflict of Interest: No  
Funding Source: No

Ali I.I.<sup>1</sup>  
Research Scholar  
Department of Microbiology, University of Karachi

Khan I.A.<sup>2</sup>  
Research Scientist  
The RNA Institute, University at Albany, NY USA

Munir M.K.<sup>3</sup>  
Research Officer  
Pakistan Medical Research Council TB Research Centre  
King Edward Medical University, Lahore

Rasool S.A.<sup>4</sup>  
Professor  
Department of Microbiology, University of Karachi

## Introduction

*Acinetobacter baumannii* is the most common isolate, among all nosocomial pathogens causing infectious epidemics in critically ill patients and prominent cause of high mortality and morbidity.<sup>1,2</sup> Currently *Acinetobacter* considered as the most harmful organism and a

major threat in clinical settings, reasoned its multi-drug resistance, permissiveness to varied degree of pH, saline nature and moisture, and its inimitable capability to endure in most of nutrients deficient environments. The burden of *Acinetobacter baumannii* is highest in hospital environments and the bacterium colonizes very effectively in hospitalized patients.<sup>3</sup>

*Acinetobacter* species are aerobic gram – negative rods which can persist for longer time in the atmosphere and can affect healthcare workers if not handle properly.<sup>4</sup> *A. baumannii*, infections has turned into progressively problematic to handle due to the manifestation of multi-drug resistance among strains or frequently recommend antibacterial drugs.<sup>5</sup> Such multi-drug resistant (MDR) strains of *Acinetobacter* are commonly sensitive to polymyxins alone i.e. colistin and polymyxin B; a group of antibacterial medicine which is more poisonous compared to current antibiotics in use and now-a-days drug of choice against *Acinetobacter* in developing countries.

*A. baumannii* causes a various type of illnesses that includes pneumonia, septicemia or localized wound infections. *A. baumannii* can colonize tracheostomy sites and open wounds in ICU patient without causing infection or showing any symptom.<sup>6</sup> *A. baumannii* can easily infect those patients stay in hospital for long period, which have open wounds and need assistance such as ventilator invasive devices and urinary catheters.<sup>7</sup> *A. baumannii* may be transmitted to healthy individuals by person-to-person interaction or through unhygienic surfaces as well as by health care workers.<sup>8</sup>

Epidemic trigger by MDR *A. baumannii* have been encountered in hospitals globally; now a days, they have developed a crucial challenge in different hospital settings.<sup>9</sup> For the molecular identification of 7 house – keeping genes consist of *glt A* (citrate synthase), *gyr B* (DNA gyrase subunit B), *gdh B* (glucose dehydrogenase B), *recA* (homologous recombination factor), *cpn60* (60-kDa chaperonin), *gpi* (glucose-6-phosphate isomerase), *rpoD* (RNA polymerase sigma factor), are commonly used for identification of *A. baumannii* isolates.<sup>10,11</sup> Owing to the high risk associated with *A. baumannii* infection in hospitals, the current study was carried to test the occurrence of *A. baumannii* in different ICUs of a tertiary care hospital of Karachi during the period from December 2010 to January 2012. There is little or no data concerning the prevalence of *A. baumannii* among health care facilities located in this region.<sup>12,13</sup>

## Material and Methods

### Selection of Cases

Three hundred and fifty patients were selected from the different ICUs of tertiary care hospital such as; medical ICUs, medical high dependency unit (HDU) and surgical ICUs (male and female) were included in this study. The consent for the participation in study was received from all the patients through a questioner prepared as per the approval of Institute Ethics Committee.

### Specimen Collection

Different samples (blood, urine, tracheal secretion, pus swab, bronchial washing, catheters, intravenous devices and tips) were collected from the patients who were admitted to the ICUs. Data on the date and site of infection, patient demographic information and the devices used were collected for microbiological processing. Only those patients were identified as one who had acquired infections after 48 h of ICU admission, as per Centers for Disease Control (CDC) guidelines for diagnosis, were included in the study.<sup>14</sup>

### Culture and Growth Requirements

Basic microbiological testing was done by standard conventional methods. Routine culture media were used as Blood agar, MacConkeys's agar, CLED (Cysteine lactose electrolyte deficient) agar, S.S. (*Salmonella* and *Shigella*) agar, Chocolate agar, SIM (Sulphur, indole and motility) medium, TSI (Triple sugar iron) agar, Simmon citrate agar and urease medium. The organisms were maintained at 4°C on agar slants and at –20°C in glycerol stocks for further analyses.

### Isolation of Pathogens and Cultural Characteristics

All standard microbiological and biochemical techniques by recommended conventional methods and standard protocols were used for isolation and identification of nosocomial pathogens.

### Antimicrobial Sensitivity Testing

Susceptibility to a panel of antimicrobial agents was tested by the disc diffusion technique reference to the national committee guidelines for Clinical Laboratory Standards Institute (CLSI).<sup>15</sup> Susceptibility pattern was established by the disk diffusion technique of Kirby –

Bauer using Mueller – Hinton agar.<sup>16</sup> Panel of antibiotics included; AMC (Amoxicilline 10 µg/ Calvulanic acid), TZP (Tazobactam 110 µg), CRO (Ceftriaxone 30 µg), CAZ (Ceftazidime 30 µg), MEM (Meropenem 10 µg), IPM (Imipenem 10 µg), G (Gentamicin 10 µg), AK (Amikacin 10 µg), C (Chloramphenicol 30 µg), SXT (Co-trimoxazole), TOB (Tobramycin 10 µg), SCF (Salbactam 30 µg / Cefoperazone 75 µg), G (Gentamicin 10 µg), AK (Amikacin 30 µg) and Polymyxin disks of 300 units were used for susceptibility testing.

### DNA Extraction

Bacterial DNA was extracted using Qiagen DNA mini (Spin Column) kit according to the manufacturer's instruction. Briefly, bacterial cells were pelleted from 5 ml of an 18 hours broth culture. Broth was centrifuged for 10 minutes at 1000 X g and re-mixed with phosphate – buffered saline with 100 µg of lysostaphin (Sigma) per milliliter, then laced in incubator at 37°C for half hour or until viscous. DNA from all preparations was subsequently extracted with Qiagen DNA protocol. DNA specimens were dissolved in TE Buffer as 10 mM Tris chloride-1mM EDTA (pH 8.0).<sup>17</sup>

### Polymerase Chain Reaction (PCR)

The presence of *glt A* gene and *gyr B* gene was used to confirm *A. baumannii* by PCR. Specific primers were used as; *glt A* (forward primer: GTAGAAATGACTG-AACGTCCGATAA while reverse primer: GTAGAA-ATGACTGAACGTCCGATAA) and *gyr B* (Forward: GCGCGACGGCAAAGAAGA and reverse: GGAAG-CCGGCGAGGTGAG).<sup>18</sup> Master mixture for PCR was made by adding buffer 2.5 µl 10x, dNTPs 0.2 mM, Taq DNA polymerase 4 Units, MgCl<sub>2</sub> 2.5 mM, and DNA template 50ng, 1.5 µl of *glt A* and *gyr B* primers respectively. Total volume was brought up to 25 µl by adding 2.5 µl of ultra-pure water. Perkin Elmer thermocycler was used for DNA amplification programmed as: preliminary denaturing at 94°C for 4 minutes was after that 35 continuous repeated sequences as denature at 94°C for 45 seconds and anneal at 58°C for 45 seconds and elongation at 72°C 60 seconds termination for an elongation at 72°C for 2 minutes. Finally PCR products, aliquot (10 µl) loaded on an ethium bromide gel (0.5 µg/ml; Sigma Ltd. USA) 1% agarose (Sigma) in Tris Borate EDTA (TBE) buffer, with known markers and run at 90V for one hour before

visualization under Ultra Violet Biodoct digital imaging system (UVP, Inc. Cambridge UK) for the presence of 722 and 909 base pair PCR products.

## Results

### Frequency of *Acinetobacter baumannii* isolates in different types of specimen collected from the hospitalized patients:

*A. baumannii* was isolated from 60% of patients with urinary catheters, 30% with different mechanical devices and 10% with central intravenous lines (Fig. 1).




Fig. 1: Frequency of *A. baumannii* in Patients.

### Susceptibility Pattern of *Acinetobacter Baumannii*

94% of *A. baumannii* were multi drug resistant (MDR) and only sensitive to Polymyxin B, 6% *A. baumannii* were also MDR but sensitive to Polymyxin B, Meropenem and Salbactam + Cefoperazone. All the isolates presented varied resistance sequences (created by medium incorporation – replica method) regarding different antibiotics listed in Table 1.

### PCR

PCR analysis showed the presence of *glt A* gene in all the 305 tested isolates. The *glt A* specific PCR products of 722 and *gyr B* specific 909 base pairs were seen in all *Acinetobacter baumannii* strains (Fig. 2 and 3).


## Discussion

*Acinetobacter baumannii* are able to survive for very long period in hospital environment and via health care workers on their hands, gloves gowns and other surfaces. These organisms can cause serious illness in hospitalized patients specifically in ICUs. Patients in ICUs need special care and precautions when they diagnosed for MDR *Acinetobacter*. Presently *glt A* (coded for citrate synthase) and *gyr B* genes were applied as the objective genes for *A. baumannii*. Out of seven house-keeping genes of *A. baumannii* only *glt A* gene and *gyr B* were obtained as the most appropriate genes to target *A. baumannii* in present study.<sup>18</sup>


The most important and foremost issue with this pathogen remained its resistance to multiple antibiotics.<sup>19,20</sup> Antimicrobial resistance against these

**Table 1:** Antibiotic resistance pattern of *Acinetobacter baumannii* (total 315).

Antibiotics	Resistance of <i>Acinetobacter</i> spp (MDR)	
	n	%
Amikacin	290	92
Amoxicillin + Calvulanic acid	305	97
Piperacillin / Tazobactam	290	92
Ceftriaxone	302	96
Ceftazidime	277	88
Gentamicin	261	83
Ciprofloxacin	284	90
Tobramycin	95	30
Imipenem	287	91
chloramphenicol	290	92
Polymixin B	-	-
Salbactam + Cefoperazone	284	90
Co-trimoxazole	290	92



**Fig. 2.**



**Fig. 3.**

drugs has delayed treatment strategies, generated growing concern globally.<sup>21-23</sup> Emergence of nosocomial or community-acquired infections of *Acinetobacter baumannii* is a result of high adaptability to adverse environmental conditions, an ability to be persist for several days in dry and harsh environments such as hospital environment, the increased use of broad spectrum antibiotics, the vulnerability of individuals or patients and rapid transformation of organisms that results in increased multidrug resistance.<sup>24</sup>

Different methods has been introduced to diagnose

*Acinetobacter* and to check the out breaks of this pathogen and to identify out break causing strains from non out breaks strains, for this purpose different tools has been used like; phenotypic identification different biochemical based reactions and antibiogram typing, phage typing and protein profiles were methods of choice but due to limitations these tools were replaced by genotypic methods.<sup>25,26</sup> Based on this we have selected *glt A* and *gyr B* genes among all seven house-keeping genes for *A. baumannii*, *glt A* gene was utilized as reference gene size of generated amplicon was

722 bp, whereas *gyr B* was selected as target for DNA gyrase subunit B and the amplicon generated by *Gyr B* primer was (909 bp). Moreover, *rpoD* gene was not used in current study because of greater length up to 54 bases of the forward and reverse primer sequences and this may reduce many bands of unspecific nature.<sup>27,28</sup>

According to our study, Ampicillin resistance was found to be most common followed by Cephalothin, Amikacin, Carbencillin, Gentamicin, Amikacin, Chloramphenicol, Tetracycline, Co-trimoxazole, Ciprofloxacin and Cefoperazone. Present study found 94%, *A. baumannii* as multi drug resistant, which were only sensitive to Polymixin B, remaining 6% were also MDR but the only difference was their resistance towards Polymixin B. Additional confirmation was done by polymerase chain reaction (PCR) of two housekeeping genes, which confirmed *Acinetobacter baumannii*. *Acinetobacter* is still a threat for causing nosocomial and health care associated infections especially in ICUs, so there is a need to move forward and help suffering patients as well as set standards.

## Acknowledgements

We would like to deeply express our thanks to Dr. Junaid Mahmood Alam and Ms. Nuzhat Ansari for their generous support and encouragement.

**Conflict of Interest:** None.

## References

1. Fournier, P.E. and H. Richet, The epidemiology and control of *Acinetobacter baumannii* in health care facilities. *Clin Infect Dis.* 2006; **42** (5): p. 692-9.
2. Giamarellou, H., A. Antoniadou, and K. Kanellakopoulou, *Acinetobacter baumannii*: a universal threat to public health? *Int J Antimicrob Agents*, 2008; **32** (2): p. 106-19.
3. Lee, K., et al., Multidrug-resistant *Acinetobacter* spp.: increasingly problematic nosocomial pathogens. *Yonsei Med J.* 2011; **52** (6): p. 879-91.
4. Sunenshine, R.H., et al., Multidrug - resistant *Acinetobacter* infection mortality rate and length of hospitalization. *Emerg Infect Dis.* 2007; **13** (1): p. 97-103.
5. Charnot - Katsikas, A., et al., Two cases of necrotizing fasciitis due to *Acinetobacter baumannii*. *J Clin Microbiol*, 2009; **47** (1): p. 258-63.
6. Talbot, G.H., et al., Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. *Clin Infect Dis.* 2006; **42** (5): p. 657-68.
7. Kilic, A., et al., *Acinetobacter septicus* sp. nov. association with a nosocomial outbreak of bacteremia in a neonatal intensive care unit. *J Clin Microbiol.* 2008. **46** (3): p. 902-8.
8. Irfan, S., et al., Metallo-beta-lactamase-producing clinical isolates of *Acinetobacter* species and *Pseudomonas aeruginosa* from intensive care unit patients of a tertiary care hospital. *Indian J Med Microbiol.* 2008; **26** (3): p. 243-5.
9. Al-Sweih, N.A., M. Al-Hubail, and V.O. Rotimi, Three distinct clones of carbapenem -resistant *Acinetobacter baumannii* with high diversity of carbapenemases isolated from patients in two hospitals in Kuwait. *J Infect Public Health*, 2012; **5** (1): p. 102-8.
10. Miglaviacca, R., et al., Characterization of resistance mechanisms and genetic relatedness of carbapenem-resistant *Acinetobacter baumannii* isolated from blood, Italy. *Diagn Microbiol Infect Dis.* 2012.
11. Lin, Y.C., et al., Genetic basis of multidrug resistance in *Acinetobacter* clinical isolates in Taiwan. *Antimicrob Agents Chemother.* 2010; **54** (5): p. 2078-84.
12. Khan, M.S., et al., Infection control education: impact on ventilator - associated pneumonia rates in a public sector intensive care unit in Pakistan. *Trans R Soc Trop Med Hyg.* 2009; **103** (8): p. 807-11.
13. Irfan, S., et al., Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. *BMC Infect Dis.* 2008; **8**: p. 80.
14. NNIS, C., National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. *Am J Infect Control*, 2004; **32** (8): p. 470-85.
15. Sader, H.S., et al., Reevaluation of Clinical and Laboratory Standards Institute disk diffusion breakpoints for tetracyclines for testing Enterobacteriaceae. *J Clin Microbiol.* 2007; **45** (5): p. 1640-3.
16. Hudzicki, J., Kirby - Bauer Disk Diffusion Susceptibility Test Protocol. ASM Microbe Library, 2012.
17. Thong, K.L., et al., Simultaneous detection of methicillin - resistant *Staphylococcus aureus*, *Acinetobacter baumannii*, *Escherichia coli*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* by multiplex PCR. *Trop Biomed.* 2011; **28** (1): p. 21-31.
18. Bartual, S.G., et al., Development of a multilocus sequence typing scheme for characterization of clinical isolates of *Acinetobacter baumannii*. *J Clin Microbiol.* 2005; **43** (9): p. 4382-90.
19. Landman, D., et al., Polymyxins revisited. *Clin Microbiol Rev.* 2008; **21** (3): p. 449-65.
20. Landman, D., et al., Citywide clonal outbreak of multi-

- resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in Brooklyn, NY: the preantibiotic era has returned. *Arch Intern Med*, 2002; **162** (13): p. 1515-20.
21. J. H. Doughari, et al., Phytochemicals as chemotherapeutic agents and antioxidants: Possible solution to the control of antibiotic resistant verocytotoxin producing bacteria. *Journal of Medicinal Plants Research*, 2009; **3** (11): p. 839-848.
22. Grotiuz, G., et al., Shiga toxin 2-producing *Acinetobacter haemolyticus* associated with a case of bloody diarrhea. *J Clin Microbiol*. 2006; **44** (10): p. 3838-41.
23. Perez, F., et al., Global challenge of multidrug – resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2007; **51** (10): p. 3471-84.
24. Joly – Guillou, M.L., Clinical impact and pathogenicity of *Acinetobacter*. *Clin Microbiol Infect*. 2005; **11** (11): p. 868-73.
25. Coyne, S., et al., Screening and quantification of the expression of antibiotic resistance genes in *Acinetobacter baumannii* with a microarray. *Antimicrob Agents Chemother*. 2010; **54** (1): p. 333-40.
26. Sydnor, E.R. and T.M. Perl, Hospital epidemiology and infection control in acute – care settings. *Clin Microbiol Rev*. 2011; **24** (1): p. 141-73.
27. Savelkoul, P.H., et al., Amplified-fragment length polymorphism analysis: the state of an art. *J Clin Microbiol*. 1999; **37** (10): p. 3083-91.
28. Gonzalez - Escalona, N., et al., Comparison of direct genome restriction enzyme analysis and pulsed-field gel electrophoresis for typing of *Vibrio vulnificus* and their correspondence with multilocus sequence typing data. *Appl Environ Microbiol*. 2007; **73** (22): p. 7494-500.